

Special Issue

Oncolytic Viruses as an Emerging Aspect of Immune Oncology

Message from the Guest Editor

Oncolytic viruses (OVs), mainly known for their ability to specifically target and cause the lysis of cancer cells, have more recently become accepted as a unique and promising aspect of immuno-oncology. Through the process of virus replication and innate responses to the infection process in tumors, the tumor microenvironment (TME) often undergoes a reprogramming and a conversion of immune suppression into immune stimulation, which can lead to potent systemic immune responses directed against distant tumor cells throughout the body. Furthermore, by heating up the TME, solid cancers can be sensitized to other forms of immunotherapy (i.e., immune checkpoint inhibitors, adoptive cell therapies, tumor vaccines, etc.) through OV treatment. Due to their multimechanistic modes of action, OVs represent an exciting approach in immuno-oncology, which can be applied either in a monotherapy setting or as components of rationally designed combination approaches for potential synergistic effects. The Special Issue aims to highlight this exciting translational approach in immuno-oncology. We are pleased to invite you to submit original contributions related to this topic.

Guest Editor

Dr. Jennifer Altomonte

Klinik und Poliklinik für Innere Medizin II, Klinikum Rechts der Isar,
Technical University of Munich, 81675 Munich, Germany

Deadline for manuscript submissions

closed (31 March 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/168678

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)